Tbhrombolytic therapy has proved effective for reduction of infarct size, preservation of ventricular function, and reduction in mortality, and it has become a standard treatment for early myocardial infarction.1-3 Failure of thrombolytic therapy may depend either on insufficient thrombolysis or on reocclusion of a successfully recanalized infarct-related artery. Intravenous streptokinase (SK) administration recanalized approximately 50% of occluded coronary arteries within 90 minutes4'5 and reduced mortality by 25%. 6, 7 Early reocclusion occurs in about 14% of successfully treated patients.5 Several studies support the hypothesis that platelet activation may limit the response to thrombolytic therapy.8 Indeed, in experimental models of coronary thrombosis, the activation of platelets may delay reperfusion and induce reocclusion. 8 The effect of thrombolytic therapy on platelets was related to the local generation of plasmin,9 the increased biosynthesis of thromboxane A2,10°1 and the transient release of active thrombin from the lysed clot.12'13 Platelet-activat-ing factor (PAF), a lipid mediator of inflammation '4-16 with direct cardiovascular effects,17-28 is also a candidate for platelet activation. Studies on isolated rabbit heart demonstrated the intracoronary release of this mediator and PAF-dependent activation of platelets during the early phase of reperfusion. 29 The observation that in rabbits treated with thrombolytic agents, PAF-receptor antagonists prevented the activation of platelets prompted us to hypothesize that PAF synthesis induced by thrombolytic agents may promote the activation of platelets. 30 The local generation of PAF and its association with endothelial cell (EC) surface may lead to platelet and/or leukocyte/endothelium interaction,31-33 thus favoring reocclusion. In the present investigation, we evaluated (1) the intravascular release of PAF in patients with acute myocardial infarction treated or untreated with intravenous SK and (2) the synthesis of PAF by cultured human umbilical vein-derived endothelial cells (ECs) challenged with SK, tissue-type plasminogen activator (t-PA), or plasmin.
Methods

Materials
SK (Streptase) was obtained from Behringwerke AG (Marburg, Germany). The chromogenic substrate (S-2251, H-D-Val-Leu-Lys pNa 2 HCl) and the human plasmin (3 casein units) used in the antiplasmin activity assays were obtained from Kabi Diagnostica, Stockholm, Sweden. D-Phenyl-L-propyl-L-arginine chloromethylketone (PPACK), a serine protease inhibitor, was obtained from Calbiochem, Frankfurt, Germany. t-PA (Actilyse) was provided by Boehringer Ingelheim, Germany. Synthetic C16 PAF (1-hexadecyl-2-acetyl-snglyceryl-3-phosphorylcholine) was obtained from Bachem Feinchemikalien, Bubendorf, Switzerland. SDZ 63-675 (Sandoz, East Hanover, NJ) and WEB 2170 (Boehringer) were used as PAF-receptor antagonists. 34, 35 60F254 thin-layer chromatography (TLC) plates were obtained from Merck (Darmstadt, Germany). Human plasmin and bovine thrombin were obtained from Sigma Chemical Co, St Louis, Mo. Culture media were obtained from Flow Laboratories (McLean, Va).
Patients
The study group consisted of consecutive patients admitted with chest pain accompanied by ST segment elevation of 1 mm or more in any limb lead of the ECG and/or of 2 mm or more in any precordial lead. They were admitted to the coronary care unit within 6 hours of the onset of symptoms. For ethical reasons, the allocation of patients to treatment could not be at random. Group A consisted of 14 patients who were treated with SK (1.5 MU in 100 mL physiological saline infused intravenously over 60 minutes). Group B included 11 patients given a control infusion of 100 mL physiological saline over a period of 60 minutes who had the following contraindications to fibrinolytic therapy: 3 patients had very recent stroke, 1 (Table) .
PAF bioactivity was detectable in peripheral blood samples of 10 of 14 patients in group A. Fig 1 shows the levels of PAF detected at different times in individual patients who reperfused and in patients who remained occluded. PAF was undetectable at all times studied in only 3 patients who reperfused and in 1 who remained occluded. Among the 10 patients with detectable intravascular amounts of PAF, 80% were positive at 90 minutes and 60% at 120 minutes after the beginning of SK infusion. All patients became negative at 24 hours. In contrast, PAF was not detectable at any time in blood samples of patients of group B whether they spontaneously reperfused or not. Therefore, the presence of PAF in peripheral circulation cannot be ascribed to thrombolysis and reperfusion per se but rather specifically to treatment with SK. In addition, PAF levels in group B patients were consistently undetectable regardless of the specific reason for exclusion from thrombolytic therapy. Group A but not group B had a progressive, significant reduction in platelet count (Fig 2A; P<.01) . The percent variation of platelet count over basal values (time 0) correlated negatively with the amount of PAF present in the circulation at 90 minutes (Fig 2B; r= -. 719, P<.001) and at 120 minutes (Fig 2C; r= - (Fig SC) submitted to the same extraction and purification procedures. was correlated with the reduction in number of circulating platelets. PAF is a phospholipid mediator of inflammation and shock that activates platelets, promoting release and aggregation. In addition to its action on platelets, PAF possesses a number of biological activities, 14- of myocardial necrosis occurring after reperfusion in several experimental models of infarction.52-55 The possible mechanism of reperfusion-induced PAF synthesis is the generation of free oxygen radicals,56'57 which have been shown to induce the synthesis of PAF by endothelium.33 In addition, the generation of oxidants may inactivate plasma antiproteinases, such as a,-antitrypsin, that inhibit the activation of cells, leading to PAF synthesis, and limit the biological sequelae of serine protease generation in plasma. 49 The observed fall in plasma concentration of a2-antiplasmin in patients infused with SK may support the contention of a reduced inhibition of plasmin activity. The results of the present study demonstrate the persistence of PAF in the circulation in amounts large enough (about 6x10-10 mol/L) to suggest that it is biologically significant, because the stimulation of platelet and neutrophil function can be detected at PAF concentrations as low as 10`to 10`'°mol/L.44 Indeed, we observed a negative correlation between the number of circulating platelets and the amount of PAF detected in blood at 60 and 120 minutes after the beginning of SK infusion, suggesting a PAF-dependent platelet activation. However, the number of platelets also tends to decrease after the exhaustion of SK-induced PAF production. This may depend on the production of thromboxane A2, as suggested by Fitzgerald et al.'0 In fact, it has recently been shown that thromboxane A2 mediates and amplifies in vivo many of the biological effects of PAF.58 Experiments performed in rabbits infused with SK and t-PA demonstrated that early thrombocytopenia is PAF dependent and can be prevented by treatment with PAF receptor antagonists. 30 In addition, a local synthesis of PAF and its association with the EC surface may induce platelet/ endothelium and polymorphonuclear neutrophil/endothelium interaction, thus favoring thrombotic reocclusion.31-33 The possible role of PAF in determining thrombotic reocclusion is also supported by experiments performed in dogs, showing that oral administration of a PAF-receptor inhibitor completely prevented reocclusion of femoral arteries after thrombolysis.59 Conversely, the negative effect of PAF may be modulated by the production of prostacyclin, which may inhibit both the synthesis of PAF and its bioactivity.42 It has been reported that whereas thrombolytic agents stimulated the synthesis of prostacyclin,60 plasmin has a potent inhibitory effect on it.61 In conclusion, the beneficial effect of thrombolytic therapy may be limited by production of endogenous mediators, including PAF, that may activate platelets locally and in systemic circulation and that may exert a direct negative inotropic and arrhythmogenic effect.l1820,22,25-27A6 The present results should stimulate further studies intended to determine whether patients with acute myocardial infarction undergoing thrombolytic therapy may benefit from concomitant treatment with PAF-receptor antagonists.
